Participant initials: | | | |

Participant ID: | | | | | |

STRESS-L

Eligibility Form

INCLUSION CRITERIA

*Participants will be excluded if **ANY** of the following are No:*	YES	NO
Aged 18 years or above	☐	☐
Being treated on an ICU	☐	☐
Septic shock according to internationally accepted definitions*	☐	☐
Heart rate ≥95 bpm (at the time of randomisation)	☐	☐
Receiving vasopressor support to maintain a target blood pressure for ≥24 hours	☐	☐
Are being treated with noradrenaline at a rate ≥ 0.1mcg/kg/min	☐	☐

*Sepsis -3 definitions:

- confirmed or suspected infection requiring antibiotic therapy
- new organ dysfunction, as evidenced by an increase in SOFA score ≥2
- a blood lactate >2 mmol/l at any point during shock resuscitation
- vasopressor therapy to maintain mean arterial pressure (MAP) ≥65 mmHg

In particular the presence of a blood lactate > 2 mmol/l is only necessary for the diagnosis of septic shock and is NOT necessary for randomisation 24 hours later.

EXCLUSION CRITERIA

*Participants will be excluded if **ANY** of the following are Yes:*	YES	NO
Tachycardia as a result of pain, discomfort from medical devices (including endotracheal tubes), during interventions or other patient distress	☐	☐
Any form of vasodilatory shock that is not caused by sepsis	☐	☐
Noradrenaline infusion <0.1mcg/kg/min	☐	☐
> 72 hours after start of vasopressor therapy	☐	☐
<12 hours since noadrenaline to treat a medical condition other than septic shock stopped		
Having pre-existing severe cardiac dysfunction (NYHA grade 4 or more)	☐	☐
Having pre-existing severe pulmonary hypertension (mean PA pressures > 55mmHg)	☐	☐
Acute severe bronchospasm (due to asthma or COPD)	☐	☐
Untreated second or third degree heart block	☐	☐
Untreated phaeochromocytoma	☐	☐
Prinzmetal's angina	☐	☐
A past history of ischaemic stroke or transient ischaemic attack (TIA) or untreated severe carotid stenosis	☐	☐
Advanced liver disease with Child-Pugh Score of ≥B	☐	☐
Known sensitivity to beta-blockers	☐	☐
Patient / legal representative unwilling to provide written informed consent	☐	☐
Known to be pregnant	☐	☐
Terminal illness other than septic shock with a life expectancy < 28 days	☐	☐
Participants who have been administered an investigational medicinal product for another research trial in the past 30 days	☐	☐
Patients in whom the clinical team feel are about to finish their noradrenaline therapy	☐	☐
Decision of withdrawal of care is in place or imminently anticipated	☐	☐
Receiving extracorporeal membrane oxygenation (ECMO) treatment		

'I confirm that this patient is eligible for enrolment in this trial'

Form completed by (*print name*):	Signature (approved investigator only):	Date: